Good morning. Oh dear, the alarm didn't go off this morning, I always struggle on Thursdays, my apologies. I'll try to catch up this evening and update this article properly, but have to dash now for another investor lunch, the third of the week. Trouble is, the networking and meeting companies is vital to out-perform, in my view - it's no good being insular, you have to soak up ideas & intelligent views from other people.

Fairpoint (LON:FRP) has issued interim figures. I bought back into this one a few weeks ago, as the valuation was beginning to look compelling again, and the shares were starting to edge up. It's since risen about 20%, so that was a good decision.

Adjusted EPS is up 12% to 5.87p for the six months, and they have moved into net cash of £2.8m. The dividend is up 10% to 2.15p, so those look good enough figures for me to sit tight on these shares. They don't comment on the outlook versus market expectations, which is annoying. I don't like waffle in outlook statements, I just want to know whether they think the full year will meet expectations or not. They do say that they are "confident of delivering a solid performance in the current year", which is reassuring, albeit too vague for my liking.

 

 

 

 

Very belatedly, I'll catch up on the rest of the day's news, as I've been out all day. It's a mid cap really, but I see that Dialight (LON:DIA) has warned on profits, with the shares down 16% to 1150p. They say that contract delays mean that profits are likely to be "broadly in line with the prior year". It did 41.3p EPS last year, so that means the shares are still far from cheap on a PER of 27.8. That's a seriously racy price for a company that is not showing any profit growth against last year - I'm surprised the shares haven't fallen considerably more, so are not of any interest to me.

 

 

 

 

Several friends hold shares in MyCelx Technologies (LON:MYXR) and it's a company I've looked at before, but the price raced away on a newspaper tip, and given the high…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here